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Abstract Inhibition of caspase-3-mediated apoptosis has been
hypothesized to be associated with chemoresistance. Investiga-
tions of apoptosis revealed that cytosolic cytochrome c is
associated with a complex of apoptotic protease activating
factor-1 (Apaf-1), an adapter molecule, and caspase-9 to activate
caspase-3. However, whether these apoptotic molecules are
involved in acquired cisplatin resistance is not understood. The
present work shows reduced activation of caspase-3 and
apoptosis in a cisplatin-selected HeLa cell line. Ac-DEVD-
CHO, a caspase-3 inhibitor, inhibited cisplatin-induced apoptosis
about 60^70% in both cell lines. Ac-LEHD-CHO, a caspase-9
inhibitor or Ac-IETD-CHO, a caspase-8 inhibitor, inhibited
cisplatin-induced caspase-3 activation and apoptosis similarly in
both cell lines. In addition, cisplatin induced the activation of
caspase-9, the upstream activator of caspase-3, in a dose-
dependent manner, and the activation of caspase-9 was less
induced in resistant cells. The accumulation of cytosolic
cytochrome c, an activator of caspase-9, and the induction of
the mitochondrial membrane-associated voltage-dependent anion
channel were also reduced in cisplatin-resistant cells. However,
the concentration of Bcl-2 family proteins in cisplatin-resistant
cells was normal. The concentration of Apaf-1 was unaltered in
both cell lines. Increasing the cellular concentration of Apaf-1
through the transient expression of the gene increased the
induction of apoptosis in resistant cells, associated with enhanced
activation of caspase-9, caspase-3 and DNA fragmentation
factor. Regression analysis reveals that the modification factor,
the ratio of the slope in the linear range of the dose^response
curve with Apaf-1 to the slope without Apaf-1, is 1.5 and 4.75 in
the HeLa and cisplatin-resistant HeLa cells, respectively. These
results indicate that apoptosis and caspases are less induced in
cisplatin-selected HeLa cells. They also suggest that ectopic
overexpression of Apaf-1 may partially reverse the acquired
cisplatin resistance. ß 2001 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Introduction
cis-Diamminedichloroplatinum(II) (cisplatin) is an impor-
tant chemotherapeutic agent for cancer treatment. The devel-
opment of resistance to cisplatin is a clinical problem, and has
led to investigation into the mechanism by which cells become
resistant to cisplatin and ways to overcome cisplatin resistance
[1^3]. The cellular response to diverse classes of stress inducers
such as cisplatin includes, among other responses, activation
of apoptosis [4,5]. Although signi¢cant biochemical changes
have been described in cell lines made resistant to cisplatin
[6^8], the role of apoptosis in cellular resistance to cisplatin
remains incompletely described.
Two of the best characterized biochemical events during
apoptosis are the activation of caspase-3 protease and the
fragmentation of DNA into nucleosomal fragments. Existing
investigations have suggested that mitochondria may play an
important role in apoptosis by releasing cytochrome c [9,10].
Cytochrome c is associated with a complex of apoptotic pro-
tease activating factor-1 (Apaf-1) and caspase-9 and thus ac-
tivates caspase-3 [11^13]. Activated caspase-3 cleaves poly-
(ADP-ribose) polymerase (PARP), protein kinase C N, and
other proteins [14,15]. Overexpression of the anti-apoptosis
Bcl-xL protein interferes with this caspase activation by pre-
venting the release of cytochrome c [9,10,16,17]. Earlier inves-
tigations have suggested that Bcl-xL (Bcl-2) may interact with
Apaf-1 and inhibit Apaf-1-mediated activation of caspase-9
[18^20]. Nucleosomal DNA fragmentation occurs during ap-
optosis following activation of the DNA fragmentation factor
(DFF), a heterodimeric protein that functions downstream of
caspase-3. DFF includes a 40 kDa factor (DFF40) and its
inhibitor DFF45, which is removed following caspase cleav-
age [21].
Several anti-cancer agents, including cisplatin, with diverse
intracellular targets cause cytosolic accumulation of cyto-
chrome c, and subsequent activation of caspase-3 [9,22,23].
However, the induction of Apaf-1, and its role in cellular re-
sistance to cisplatin, remains obscure. The present investiga-
tion found that apoptosis and caspase activation are less in-
duced in cisplatin-selected HeLa cells. Additionally, ectopic
overexpression of Apaf-1 partially reverses the acquired cis-
platin resistance.
2. Materials and methods
2.1. Cell lines and culture
Human cervix carcinoma HeLa and cisplatin-resistant HeLa cells
(HeLa-CPR) [8] were maintained in Dulbecco’s modi¢ed Eagle’s me-
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dium (Gibco, Gaithersburg, MD, USA) supplemented with 10% fetal
calf serum, penicillin (100 U/ml) and streptomycin (100 Wg/ml; Gib-
co). The cell lines were maintained at 37‡C in a humidi¢ed atmos-
phere of 5% CO2 and 95% air. 1 WM cisplatin was added to the
medium to maintain the resistant phenotype. Before any experiments,
resistant cells intended as source materials were cultivated in media
without cisplatin for 3 weeks.
2.2. Western blot analysis
Cells (2U106) were treated with cisplatin, washed twice with phos-
phate-bu¡ered saline (PBS) and lysed in a lysis bu¡er (RIPA, Tris^
HCl 50 mM, pH 7.4, NP-40 1%, sodium deoxycholate 0.25%, NaCl
150 mM, EGTA 1 mM, phenylmethylsulfonyl £uoride (PMSF) 1 mM,
protease inhibitor cocktail, Na3VO4 1 mM and NaF 1 mM) on ice for
30 min. Insoluble material was removed by centrifugation at 14 000
rpm for 10 min at 4‡C. Protein concentrations were measured using a
protein assay kit (Bio-Rad, Hercules, CA, USA). Proteins were sepa-
rated by SDS^PAGE, transferred onto PVDF membranes and incu-
bated with antibodies reactive to CPP32/caspase-3, PARP, Apaf-1,
caspase-9, voltage-dependent anion channel (VDAC), Bcl-xL, Bcl-2,
Bax or DFF (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
antigen^antibody complexes were visualized by standard enhanced
chemiluminescence reaction (Pierce, Rockford, IL, USA). Rabbit
anti-caspase-9 was kindly provided by Dr. Xiaodong Wang, Univer-
sity of Texas Southwestern Medical Center.
2.3. Analysis of apoptosis
Cells growing in six-well plates were either left untreated or treated
with cisplatin for 24 h. For inhibitor investigations, cells were prein-
cubated with a caspase-3 inhibitor, Ac-DEVD-CHO, or caspase-9
inhibitor, Ac-LEHD-CHO, or caspase-8 inhibitor, Ac-IETD-CHO
(Bachem, Switzerland), for 2 h. The cells were ¢xed with methanol
and incubated with DAPI (4-diamidino-2-phenylindole) solution for
30 min in darkness. Floating cells from each well were also ¢xed and
returned to the respective wells. All cells were analyzed using an
Olympus microscope at 420 nm. Apoptotic cells exhibiting morpho-
logic features of apoptosis, including chromatin condensation and
nuclear fragmentation [24], were counted in six to eight randomly
selected ¢elds. Approximately 500 nuclei were examined for each sam-
ple, and the results are expressed as the number of apoptotic nuclei
over the total number of nuclei counted.
2.4. Determination of cytochrome c release
Cells were washed twice with PBS, and suspended in bu¡er A (20
mM HEPES, pH 7.5, 1.5 mM MgCl2, 10 mM KCl, 1 mM EDTA,
1 mM EGTA, 1 mM dithiothreitol, 0.1 mM PMSF, and protease
inhibitor cocktail) with 250 mM sucrose for 30 min on ice. The cells
were then run through a Dounce homogenizer 15 times with a sand
paper-polished pestle. Following centrifugation for 5 min at 4‡C the
supernatants were further centrifuged at 100 000Ug for 30 min at 4‡C.
The resulting supernatant served as the soluble cytosolic fraction.
Proteins were separated by SDS^PAGE, transferred onto PVDF
membranes, and probed with anti-cytochrome c antibody (Santa
Cruz Biotechnology).
2.5. Construction and production of recombinant adenovirus
Replication-de¢cient recombinant adenoviruses containing Apaf-1
were generated using the method described by He et al. [25]. Brie£y,
a 4.2 kb NotI/EcoRV fragment was isolated from pcDNA 3.1-Apaf-1
[11] and ligated with pAdTrack-CMV [25]. Following restriction en-
zyme mapping, linearized pAdTrack-CMV-Apaf-1 was cotransformed
with pAdEasy1 into BJ5183 competent bacteria to generate recombi-
nant pAdEasy1-GFP-Apaf-1. The genomic structure of pAdEasy1-
GFP-Apaf-1 was con¢rmed by restriction mapping. Recombinant vi-
ruses were produced by transfecting linearized pAdEasy1-GFP-Apaf-1
into 293 cells using lipofectamine reagent (Gibco). For large-scale
virus production, the recombinant viruses were harvested from 20
plates of 293 cells grown on a 10 cm dish following 48 h of infection
and subjected to CsCl gradient centrifugation [26]. Following desalt-
ing by PD-10 Sephadex column (Pharmacia), the viruses were ali-
quoted and stored at 370‡C. The titer of the viruses was determined
using a spectrophotometer at 260 nm, with one OD260 representing
approximately 1012 pfu/ml.
2.6. Overexpression of adenovirus-mediated Apaf-1
Cells growing in the log phase were infected with either empty
vector or Apaf-1 adenovirus. After 36 h, cells were either left un-
treated or treated with various concentrations of cisplatin for 24 h.
Cells were washed with PBS and stained with DAPI to analyze the
morphology and percentage of apoptotic cells. Samples were scruti-
nized under a microscope (Olympus, Japan). 50^60% of the cells be-
came infected by the virus (multiplicity of infection, MOI, 500) as
indicated by the green £uorescence.
Fig. 1. Reduced activation of caspase-3 in resistant HeLa cells. A:
Reduced activation of caspase-3 by cisplatin in resistant cells. HeLa
and HeLa-CPR cells were either left untreated as controls (C) or
treated with indicated concentrations of cisplatin for 24 h. Immuno-
blot analysis of the lysates was conducted with anti-caspase-3 or
anti-PARP. The molecular weight markers (in kDa) are displayed
on the left. B: Delayed activation of caspase-3 by cisplatin in resis-
tant cells. Cells were treated with cisplatin (40 WM), harvested at in-
dicated time points and immunoblotted with anti-caspase-3 or anti-
PARP. C: Reduction of cisplatin-induced apoptosis with a caspase-
3 inhibitor in both cell lines. Cells were pretreated with Ac-DEVD-
CHO, a caspase-3 inhibitor, for 2 h and continuously treated to-
gether with indicated concentrations of cisplatin for 24 h. The per-
centage of apoptosis was determined by DAPI staining and micros-
copy. The plotted values denote the mean þ S.D. of three
independent experiments.
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3. Results
3.1. Reduced activation of caspase-3 in cisplatin-resistant cells
Caspases are believed to be vital in mediating various apo-
ptotic responses, including those mediated by cisplatin. To
examine the role of apoptotic response in acquired cisplatin
resistance, we ¢rst measured caspase-3 activation and apopto-
sis in a cisplatin-selected cell line. Caspase-3 was cleaved pro-
teolytically from its inactive precursor form into active frag-
ments by using cisplatin at a concentration of 40 WM in HeLa
cells (Fig. 1A). Consistent with caspase-3 activation by cispla-
tin, the caspase-3 substrate protein, PARP, was also cleaved
Fig. 2. Inhibition of cisplatin-induced caspase-3 activation and apoptosis by caspase-9 and -8 inhibitors. A: Inhibition of cisplatin-induced cas-
pase-9 and -8 activation reduced the caspase-3 activation in both cells. HeLa and HeLa-CPR cells were either left untreated or pretreated with
Ac-LEHD-CHO, a caspase-9 inhibitor, or Ac-IETD-CHO, a caspase-8 inhibitor, for 2 h and continuously treated together with indicated con-
centrations of cisplatin for 24 h. Immunoblot analysis of the lysates was conducted with anti-caspase-3. The molecular weight markers (in kDa)
are displayed on the left. B: Inhibition of cisplatin-induced apoptosis by caspase-9 and -8 inhibitors in both cells. HeLa and HeLa-CPR cells
were treated similarly as in A. The percentage of apoptosis was determined by DAPI staining and microscopy. The plotted values denote the
mean þ S.D. of three independent experiments.
Fig. 3. Reduced induction of Apaf-1, cytochrome c release and caspase-9 activation in resistant HeLa cells. Cells were either left untreated (C)
or treated with indicated concentrations of cisplatin for 24 h. Immunoblot analysis was conducted with anti-Apaf-1 (A), anti-caspase-9 (B),
anti-VDAC (D) or anti-Bcl-xL (E). To study cytochrome c, cells were treated with cisplatin and harvested after 8 h. Cytosolic fractions were
prepared as described in Section 2, and immunoblot analysis was performed with anti-cytochrome c (C).
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from its 116 kDa to an 85 kDa fragment. However, the same
treatment did not activate caspase-3 in resistant cells. At high-
er cisplatin concentrations, for example 120 WM, the caspase
was e¡ectively activated in resistant HeLa-CPR cells. Kinetic
investigations also demonstrated that caspase-3 and PARP
cleavage became active after 24 h at 40 WM of cisplatin in
HeLa cells, but were either inactive or only minimally active
in resistant cells (Fig. 1B). To determine whether caspase-3
activation is required for cisplatin-induced apoptosis, this
pathway was inhibited using the caspase-3 inhibitor Ac-
DEVD-CHO [27]. As illustrated in Fig. 1C, pretreatment of
cells with a sublethal concentration of the caspase-3 inhibitor
(35 WM) inhibited cisplatin-induced apoptosis about 60^70%
in both cell lines. These experimental results reveal that
although resistant cells display reduced apoptosis, the apopto-
sis machinery is probably not defective.
It is known that caspase-3 is a downstream e¡ector of cas-
pase-8 and caspase-9 in the apoptosis pathway [28^30]. To
assess the upstream signal, resistant cells were compared
with sensitive cells for their response to cisplatin with or with-
out speci¢c inhibitors for caspase-8, Ac-IETD-CHO, or cas-
pase-9, Ac-LEHD-CHO. As shown in Fig. 2A, caspase-3 was
activated in sensitive and resistant cells by 20 WM and 60 WM
of cisplatin, respectively. In the presence of either inhibitor of
caspase-8 or caspase-9, caspase-3 activation was reduced. This
inhibitory e¡ect was also observed in apoptosis. As shown in
Fig. 2B, about 70% of cisplatin-induced apoptosis was inhib-
ited in 20 and 60 WM-treated HeLa and HeLa-CPR cells,
respectively, in the presence of either caspase-8 or -9 inhibitor.
The results support the notion that the activation of caspase-3
upstream signal is also reduced in resistant cells, and that
inhibition of caspase-8 or -9 activation blocks apoptosis sim-
Fig. 4. Enhancement of cisplatin-induced apoptosis by overexpression of Apaf-1. The percentage of apoptotic cells was determined by DAPI
staining of the infected cells. Cells infected with the empty vector or Apaf-1 adenovirus (MOI 500) were treated with cisplatin as indicated. The
plotted values denote the mean þ S.D. of three independent experiments.
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ilarly in both cell lines. These results also suggest that the
apoptotic machinery is likely unaltered in resistant cells, com-
pared to sensitive parental cells.
3.2. Reduced induction of cytochrome c release and caspase-9
activation in cisplatin-resistant cells
To reveal the upstream factor for reduced activation of
caspase-3 in resistant cells, upstream caspases and their regu-
lators were determined. Cytochrome c and dATP-dependent
formation of the Apaf-1/caspase-9 complex has been demon-
strated to activate caspase-3 [11^13]. In the present study,
activation of caspase-9 was induced by cisplatin in a dose-
dependent manner in both cell lines, but less in resistant cells
(Fig. 3A). Here, only caspase-9 precursor was shown whose
intensity decreased with drug concentration. Among the e¡ec-
tors of caspase-9 activation by the same treatment, the Apaf-1
level remained unchanged (Fig. 3B). Cytochrome c relocalized
from mitochondria to the cytosol during apoptotic stimuli. To
examine the role of cytochrome c, the accumulation of cyto-
chrome c in partially fractionated cytosol was monitored. As
con¢rmed in Fig. 3C, cisplatin caused cytochrome c accumu-
lation in both cell types in a dose-dependent manner. How-
ever, induction in resistant cells was less than in sensitive cells.
VDAC is an abundant protein in the outer mitochondrial
membrane that forms a large voltage-gated pore in the planar
lipid bilayers [31] and seems to serve, in combination with
Bax, as a pathway for cytochrome c release from mitochon-
dria. To test this hypothesis, we examined the induction of
VDAC and its regulatory proteins Bcl-xL, Bcl-2 and Bax.
Cisplatin was found to increase VDAC concentration in a
dose-dependent manner in both sensitive and resistant cells
(Fig. 3D). However, the induction was reduced in resistant
cells. Although slight induction of Bcl-xL by cisplatin oc-
curred in both cell types (Fig. 3E), only trace levels of Bcl-2
and Bax were induced, the protein levels remained largely
unaltered (data not shown). Notably, the concentrations of
these apoptotic proteins and regulators are the same in both
cell lines. Thus, the resistant HeLa cells exhibited reduced
activation of caspase-9 and reduced accumulation of cyto-
chrome c release and VDAC. However, the concentration of
Bcl-2 family proteins appeared normal in the resistant cells
subjected to cisplatin.
3.3. Overexpression of Apaf-1 reverses the cisplatin-induced
apoptotic resistance
It has been demonstrated that a reduced Apaf-1 level is
associated with reduced apoptosis in cells, such as melanoma,
resistant to chemotherapeutic drugs [32]. To determine the
role of Apaf-1 in cisplatin resistance, we overexpressed
Apaf-1 by adenovirus-transduced Apaf-1 cDNA in both cells.
Fig. 5. Enhancement of cisplatin-induced activation of caspase-9, -3 and DFF by overexpression of Apaf-1. A: Overexpression of Apaf-1 in
cells infected with adenovirus carrying the Apaf-1 gene. Cells were infected either with empty vector adenovirus (C) or with Apaf-1 adenovirus
(MOI 500). Cells were harvested after the indicated times (top panel) or at 36 h (bottom panel) for immunoblot analysis with anti-Apaf-1.
B: Enhancement of cisplatin-induced activation of caspase-9, -3 and DFF by overexpression of Apaf-1. Cells were infected with Apaf-1 adeno-
virus (MOI 500), and after 36 h they were treated with cisplatin as indicated for 24 h. Immunoblot analysis of the lysates was performed with
anti-caspase-9, anti-caspase-3, anti-PARP or anti-DFF.
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Following cisplatin treatment, apoptotic cells with chromatin
condensation and nuclear fragmentation were counted. Apaf-
1 overexpression signi¢cantly enhanced cisplatin-induced ap-
optosis in parental and HeLa-CPR cells, and caused a greater
enhancement of cisplatin-induced apoptosis by Apaf-1 in re-
sistant cells (Fig. 4). Regression analysis reveals that the mod-
i¢cation factor, the ratio of the slope in the linear range of
dose^response curve with Apaf-1 to the slope without Apaf-1,
is 1.5 and 4.75 in the HeLa and HeLa-CPR cells, respectively.
Only cells infected with the virus (50^60%) as shown by green
£uorescence were sampled.
Further, we examined whether overexpression of Apaf-1
could a¡ect the cisplatin-induced activation of caspase-9, cas-
pase-3 and DFF. Transient expression of Apaf-1 was detected
in HeLa/Apaf-1 and HeLa-CPR/Apaf-1 cells. Kinetic expres-
sion of Apaf-1 indicated that the Apaf-1 level increased to a
maximum at 24 h following infection (Fig. 5A). The basal
level and the optimized expression level of Apaf-1, 36 h after
virus infection, appeared 1.5^2-fold increased in both cell
lines. The activation of caspase-9 increased with cisplatin con-
centration in both cells (Fig. 5B). Overexpression of Apaf-1
enhanced cisplatin-induced activation of caspase-9 by 1.5^2-
fold (estimated by densitometry of the X-ray ¢lms) in both
HeLa and HeLa-CPR cells. Caspase-3, a downstream e¡ector
caspase to caspase-9, was also enhanced by Apaf-1 overex-
pression as determined by the increased formation of cleaved
products. The latter was con¢rmed by enhanced PARP cleav-
age by caspases. Since chromosomal fragmentation involves
activation of DFF, the activation of DFF was also investi-
gated. The intensity of the DFF precursor was slightly de-
creased, an indication of enhanced DFF activation, by cispla-
tin in both HeLa and HeLa-CPR cells. Overexpression of
Apaf-1 enhanced cisplatin-induced activation of DFF by
1.5^2-fold (estimated by densitometry of the X-ray ¢lms) in
both cells. These results support the notion that nuclear apo-
ptosis is dependent on the activation of cytosolic caspases
including caspase-3. These ¢ndings further strengthen the hy-
pothesis that overexpression of Apaf-1 may partially reverse
the acquired cisplatin resistance.
4. Discussion
In this report, we found reduced activation of caspase-3 and
PARP cleavage in cisplatin-resistant cells compared to sensi-
tive HeLa cells. Pretreatment of cells with the caspase-3 in-
hibitor Ac-DEVD-CHO inhibited cisplatin-induced apoptosis
in both sensitive and resistant cells. Others have also shown
that alteration in the expression of caspase-3 is associated
with the development of cellular resistance to cisplatin [33].
These results support the notion that activation of caspase-3 is
critical in the control of cisplatin-induced apoptosis in mam-
malian cells. Previous investigations have a⁄rmed that vari-
ous apoptotic stimuli other than cisplatin also activate cas-
pase-3 and PARP cleavage [34^36]. Since inhibition of
caspase-8 and -9 activation reduced the activation of cas-
pase-3 and blocked apoptosis similarly in both cell lines, the
apoptotic machinery in resistant cells is likely unaltered.
Although reduced induction of caspase-3 mediated apoptosis
in resistant cells, our ¢ndings suggest that the apoptotic ma-
chinery is likely unaltered.
Recent investigations con¢rmed that Apaf-1 exerts its e¡ect
by interacting with and promoting the oligomerization of pro-
caspase-9, resulting in the sequential cleavage and activation
of caspase-9 and caspase-3 [37]. The cellular concentration of
Apaf-1 has also been reported to be an important molecular
determinant of the threshold for apoptosis induced by pacli-
taxel, etoposide [38] and cisplatin [39,40]. Although the Apaf-
1 level was not changed after cisplatin treatment as shown in
HeLa cells, still the concentration of this molecule may be
in£uential in apoptosis induced by drugs, and in the develop-
ment of drug resistance. Unexpectedly, overexpression of
Apaf-1 caused an equal e¡ect on DFF activation, while it
di¡erentially modi¢ed apoptosis (i.e. chromosomal DNA
fragmentation and chromatin condensation) by cisplatin in
sensitive and resistant cells. Since DFF is a major activator
for chromosomal DNA fragmentation [21], chromatin con-
densation can also be regulated by Apaf-1, and it is di¡er-
entially regulated in the sensitive and resistant cells. These
experimental results suggest that Apaf-1 may modify other
factors involved in cisplatin-induced apoptosis besides DFF.
Diverse apoptosis-inducing agents, including UVB light,
staurosporine, etoposide, actinomycin D and ara-C, can pro-
voke the release of cytochrome c from mitochondria [10^
12,32]. Inhibition of cytochrome c release is associated with
acquired resistance to cytotoxic drugs [41]. Cells undergoing
apoptosis were found to exhibit elevated cytochrome c in the
cytosol, while overexpression of Bcl-2 prevented the e¥ux of
cytochrome c from the mitochondria and the initiation of
apoptosis by interacting with the mitochondrial channel
VDAC [9,18,42]. Correlating with these reports, our results
also displayed a signi¢cantly increased cytochrome c accumu-
lation in cytosol following cisplatin treatment, and reduced
induction of cytochrome c release in the cisplatin-resistant
cells. Although cisplatin induced the expression of VDAC
and Bcl-xL in sensitive and resistant HeLa cells, they only
di¡ered from the other samples in the induction of VDAC.
However, both cell types expressed minimal levels of Bcl-2
and Bax, and their levels did not change signi¢cantly follow-
ing cisplatin treatment (data not shown). Similarly, no change
occurred in Bcl-2 following cisplatin treatment in either pa-
rental or cisplatin-resistant ovarian carcinoma cells [43]. The
above results imply that controlling cytochrome c release is
important for the resistance mechanism in HeLa cells.
Additionally, this investigation con¢rmed that overexpres-
sion of Apaf-1 enhances the susceptibility of cells to cisplatin-
induced apoptosis and partially reverses cisplatin-induced
apoptotic resistance. Although the basal level of Apaf-1 ap-
peared to be similar in both cell lines, the modi¢cation of
apoptosis is greater in resistant cells suggesting that overex-
pressed Apaf-1 itself may readily induce apoptosis in resistant
cells through oligomerization [44]. Unlike apoptosis, which is
determined only in infected cells, the fact that the modi¢ca-
tion in the activation of caspases in resistant cells is less com-
pared to apoptosis may be due to mixed populations of un-
infected and infected cells. Since the activation of Apaf-1
depends on the presence of dATP and cytochrome c [11,12],
the two-fold reduced induction of apoptosis by cisplatin in
resistant cells may be the result of reduced cytochrome c re-
lease. However, it has already been con¢rmed that DNA re-
pair is enhanced two- to three-fold in the resistant cells [8,45].
Reduced cytochrome c release in cisplatin-resistant cells is
unlikely to be in£uential besides enhancing DNA repair in
acquired apoptotic resistance. Since our data suggest that
the caspase signaling is unaltered in resistant HeLa cells,
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reduced activation of caspase-9 and -3 in cisplatin resistance is
probably signaled from upstream of the caspase pathway.
Therefore, induction of cytochrome c release by cisplatin
may be associated with DNA damage. Nevertheless, reduced
induction of cytochrome c release in response to cisplatin
damage can clearly cause reduced apoptosis through reduced
caspase-9 and caspase-3 activity. This phenomenon may es-
tablish an opportunity for cells to develop resistance to cis-
platin. Taken together, our results suggest that enhanced
DNA repair in cisplatin-selected cells may be responsible for
reduced apoptosis.
In summary, our results indicate that apoptosis and caspase
activation are less induced in cisplatin-selected HeLa cells.
Although Apaf-1 is not induced more in resistant cells, ectopic
overexpression may partially reverse the acquired cisplatin re-
sistance. Therefore, Apaf-1 can be a potential target for gene
therapy against cancer. Although reduced induction of cyto-
chrome c release and caspase activation may lead to apoptotic
resistance, a role of Bcl-2 and Bcl-xL in regulating Apaf-1
activation cannot be ruled out. Further studies are needed
to determine if our ¢ndings apply to other tumor cell models.
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